an Istitution Experience on Parosteal OsTeosarcoma
NCT03768076 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220
Last updated 2021-08-05
Summary
single institution cases series review of histological and clinical data
Conditions
- Parosteal Osteosarcoma
Sponsors & Collaborators
-
Istituto Ortopedico Rizzoli
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-11-30
- Primary Completion
- 2019-02-28
- Completion
- 2019-02-28
Countries
- Italy
Study Locations
More Related Trials
-
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
NCT01654692 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
NCT00942162 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
NCT02780089 ·Status: COMPLETED
-
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT02107755 ·Status: COMPLETED ·Phase: PHASE2
-
The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany
NCT03205722 ·Status: WITHDRAWN
-
Investigation of Desmoplastic Squamous Cell Carcinoma
NCT02717936 ·Status: UNKNOWN ·Phase: NA
-
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT06400550 ·Status: RECRUITING
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Extension In Cancer Patients
NCT00830180 ·Status: COMPLETED ·Phase: PHASE2
-
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
NCT01511913 ·Status: COMPLETED
-
Immune Monitoring in Metastatic Melanoma
NCT04158544 ·Status: UNKNOWN
-
Understanding and Anticipating Therapeutic Response And Immuno-meDIated Adverse Events in Anti-cancer Immune-checkpoint Inhibition: a Tissue Biopsy Based imaGing Study
NCT05921123 ·Status: RECRUITING
-
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
NCT05561491 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France
NCT04550247 ·Status: ACTIVE_NOT_RECRUITING
-
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
NCT05984615 ·Status: COMPLETED
-
A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX
NCT02383901 ·Status: COMPLETED
-
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
NCT04146324 ·Status: COMPLETED
-
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
NCT01310816 ·Status: COMPLETED ·Phase: PHASE2
-
Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies
NCT03673332 ·Status: TERMINATED ·Phase: PHASE4
-
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
NCT03165422 ·Status: COMPLETED
-
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
NCT06727630 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients
NCT05615883 ·Status: COMPLETED ·Phase: NA
-
Passive Versus Active Educational Interventions for Melanoma Recognition
NCT04507048 ·Status: COMPLETED ·Phase: NA
-
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
NCT03605771 ·Status: RECRUITING
-
Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma
NCT06710093 ·Status: NOT_YET_RECRUITING